Switch to
More onapp

Suven Life Sciences Ltd

SUVEN
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,316 cr, stock is ranked 947
Moderate RiskStock is 2.69x as volatile as Nifty
59.351.00 (-1.66%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,316 cr, stock is ranked 947
Moderate RiskStock is 2.69x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
-10.79
PB RatioPB Ratio
13.69
Dividend YieldDiv. Yield
Sector PESector PE
33.80
Sector PBSector PB
4.14
Sector Div YldSctr Div Yld
0.93%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Suven Life Sciences Limited is a bio-pharmaceutical company, engaged in the business of manufacture and sale of bulk drugs and intermediaries.

Financial TrendFinancial statements 

2019202020212022312.9228.4521.2317.16-23.90-94.22-72.16-121.99
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has increased by 4.59%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Statement of deviation(s) or variation(s) under Reg. 32 
Announced OnFeb 2, 2023

Suven Life Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 | Download

Suven Life Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 | Download

Financial Result Updates 
Announced OnFeb 2, 2023

Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2022. | Download

Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2022. | Download

Cash Dividend 
Ex. DateFeb 17, 2021

Interim • Div/Share: ₹ 1

See all events